Semaglutide Reduces Heart Event and Fatty Liver Risk in Obese Adults
Recent analysis of international clinical trials confirms that semaglutide—the active compound in Wegovy and Ozempic—significantly reduces the risk of major adverse cardiovascular events (MACE) and fatty liver disease in adults ... Read More